Milrinone in the treatment of chronic cardiac failure

A controlled trial

Mariell J. Likoff, Karl Weber, Virginia Andrews, Joseph S. Janicki, Hugh Wilson, Mario L. Rocci

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This study examines the acute hemodynamic response to intravenous and oral milrinone in 12 patients with moderate to moderately severe heart failure. The patients received milrinone or placebo at random in an 8-week double-blind trial. Dosing level and schedule were determined by the hemodynamic results. Acute and chronic plasma samples for milrinone concentration were drawn from patients throughout the study. Milrinone was administered intravenously in successive doses of 25, 50, and 75 μg/kg. This resulted in a 16.5%, 12.5%, and 28.4% peak increase in cardiac index, with a concomitant 24%, 29%, and 38% decrease in pulmonary capillary wedge pressure. There were no significant relationships between any of the mean maximal hemodynamic values and milrinone plasma concentration. Six patients received milrinone and six patients received placebo; only five patients completed the blinded phase. There was no significant difference between the groups in exercise capacity, but the conditions of five of the six patients who received placebo deteriorated. In two of the patients who received milrinone the aerobic capacity improved >2 cc/min/kg over baseline, and an additional two patients reported a marked subjective improvement. The results of this study indicate that oral milrinone in the management of patients with chronic cardiac failure would justify larger controlled studies.

Original languageEnglish (US)
Pages (from-to)1035-1042
Number of pages8
JournalAmerican Heart Journal
Volume110
Issue number5
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Milrinone
Heart Failure
Therapeutics
Hemodynamics
Placebos
Pulmonary Wedge Pressure
Appointments and Schedules

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Likoff, M. J., Weber, K., Andrews, V., Janicki, J. S., Wilson, H., & Rocci, M. L. (1985). Milrinone in the treatment of chronic cardiac failure: A controlled trial. American Heart Journal, 110(5), 1035-1042. https://doi.org/10.1016/0002-8703(85)90206-6

Milrinone in the treatment of chronic cardiac failure : A controlled trial. / Likoff, Mariell J.; Weber, Karl; Andrews, Virginia; Janicki, Joseph S.; Wilson, Hugh; Rocci, Mario L.

In: American Heart Journal, Vol. 110, No. 5, 01.01.1985, p. 1035-1042.

Research output: Contribution to journalArticle

Likoff, MJ, Weber, K, Andrews, V, Janicki, JS, Wilson, H & Rocci, ML 1985, 'Milrinone in the treatment of chronic cardiac failure: A controlled trial', American Heart Journal, vol. 110, no. 5, pp. 1035-1042. https://doi.org/10.1016/0002-8703(85)90206-6
Likoff, Mariell J. ; Weber, Karl ; Andrews, Virginia ; Janicki, Joseph S. ; Wilson, Hugh ; Rocci, Mario L. / Milrinone in the treatment of chronic cardiac failure : A controlled trial. In: American Heart Journal. 1985 ; Vol. 110, No. 5. pp. 1035-1042.
@article{41447a8fba654bfd8168f4d8087932f4,
title = "Milrinone in the treatment of chronic cardiac failure: A controlled trial",
abstract = "This study examines the acute hemodynamic response to intravenous and oral milrinone in 12 patients with moderate to moderately severe heart failure. The patients received milrinone or placebo at random in an 8-week double-blind trial. Dosing level and schedule were determined by the hemodynamic results. Acute and chronic plasma samples for milrinone concentration were drawn from patients throughout the study. Milrinone was administered intravenously in successive doses of 25, 50, and 75 μg/kg. This resulted in a 16.5{\%}, 12.5{\%}, and 28.4{\%} peak increase in cardiac index, with a concomitant 24{\%}, 29{\%}, and 38{\%} decrease in pulmonary capillary wedge pressure. There were no significant relationships between any of the mean maximal hemodynamic values and milrinone plasma concentration. Six patients received milrinone and six patients received placebo; only five patients completed the blinded phase. There was no significant difference between the groups in exercise capacity, but the conditions of five of the six patients who received placebo deteriorated. In two of the patients who received milrinone the aerobic capacity improved >2 cc/min/kg over baseline, and an additional two patients reported a marked subjective improvement. The results of this study indicate that oral milrinone in the management of patients with chronic cardiac failure would justify larger controlled studies.",
author = "Likoff, {Mariell J.} and Karl Weber and Virginia Andrews and Janicki, {Joseph S.} and Hugh Wilson and Rocci, {Mario L.}",
year = "1985",
month = "1",
day = "1",
doi = "10.1016/0002-8703(85)90206-6",
language = "English (US)",
volume = "110",
pages = "1035--1042",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Milrinone in the treatment of chronic cardiac failure

T2 - A controlled trial

AU - Likoff, Mariell J.

AU - Weber, Karl

AU - Andrews, Virginia

AU - Janicki, Joseph S.

AU - Wilson, Hugh

AU - Rocci, Mario L.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - This study examines the acute hemodynamic response to intravenous and oral milrinone in 12 patients with moderate to moderately severe heart failure. The patients received milrinone or placebo at random in an 8-week double-blind trial. Dosing level and schedule were determined by the hemodynamic results. Acute and chronic plasma samples for milrinone concentration were drawn from patients throughout the study. Milrinone was administered intravenously in successive doses of 25, 50, and 75 μg/kg. This resulted in a 16.5%, 12.5%, and 28.4% peak increase in cardiac index, with a concomitant 24%, 29%, and 38% decrease in pulmonary capillary wedge pressure. There were no significant relationships between any of the mean maximal hemodynamic values and milrinone plasma concentration. Six patients received milrinone and six patients received placebo; only five patients completed the blinded phase. There was no significant difference between the groups in exercise capacity, but the conditions of five of the six patients who received placebo deteriorated. In two of the patients who received milrinone the aerobic capacity improved >2 cc/min/kg over baseline, and an additional two patients reported a marked subjective improvement. The results of this study indicate that oral milrinone in the management of patients with chronic cardiac failure would justify larger controlled studies.

AB - This study examines the acute hemodynamic response to intravenous and oral milrinone in 12 patients with moderate to moderately severe heart failure. The patients received milrinone or placebo at random in an 8-week double-blind trial. Dosing level and schedule were determined by the hemodynamic results. Acute and chronic plasma samples for milrinone concentration were drawn from patients throughout the study. Milrinone was administered intravenously in successive doses of 25, 50, and 75 μg/kg. This resulted in a 16.5%, 12.5%, and 28.4% peak increase in cardiac index, with a concomitant 24%, 29%, and 38% decrease in pulmonary capillary wedge pressure. There were no significant relationships between any of the mean maximal hemodynamic values and milrinone plasma concentration. Six patients received milrinone and six patients received placebo; only five patients completed the blinded phase. There was no significant difference between the groups in exercise capacity, but the conditions of five of the six patients who received placebo deteriorated. In two of the patients who received milrinone the aerobic capacity improved >2 cc/min/kg over baseline, and an additional two patients reported a marked subjective improvement. The results of this study indicate that oral milrinone in the management of patients with chronic cardiac failure would justify larger controlled studies.

UR - http://www.scopus.com/inward/record.url?scp=0022250570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022250570&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(85)90206-6

DO - 10.1016/0002-8703(85)90206-6

M3 - Article

VL - 110

SP - 1035

EP - 1042

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -